致死性非未分化滤泡细胞来源甲状腺癌的临床病理特征
该研究分析了1985至2010年间在一家三级癌症中心手术的3750例非未分化滤泡细胞来源甲状腺癌,其中58例(1.5%)死于该病。死亡病例主要由低分化癌(57%)和高细胞变异型乳头状甲状腺癌(24%)构成,几乎所有死亡病例均存在远处转移、低分化癌、甲状腺外侵犯或广泛血管侵犯中的至少一项。大多数患者死于远处转移而非局部区域侵犯,提示需要有效的全身治疗。
要点
- 低分化癌和高细胞变异型乳头状甲状腺癌占分化型甲状腺癌死亡的绝大多数。
- 死亡病例中,47%初诊时即有远处转移,48%随访期间发生远处转移。
- 所有死亡患者在诊断时至少具备远处转移、低分化癌、甲状腺外侵犯或广泛血管侵犯中的一项。
核心结论
- 低分化癌和高细胞变异型乳头状甲状腺癌是分化型甲状腺癌死亡的主要原因。
- 少数致死的经典型、滤泡变异型乳头状甲状腺癌和微小癌均伴有低分化癌成分、远处转移或甲状腺外侵犯。
- 初诊时无远处转移、无低分化癌、无甲状腺外侵犯且无广泛血管侵犯的甲状腺癌几乎无死亡风险。
- 绝大多数患者死于远处转移而非局部区域侵犯,促使需要有效的全身治疗。
研究设计与样本
- 回顾性分析1985年至2010年间在一家三级癌症中心手术的所有非未分化滤泡细胞来源甲状腺癌患者,共3750例,其中58例(1.5%)为死于该病者,并对其进行细致的临床病理分析。
主要发现
- 3750例非未分化滤泡细胞来源甲状腺癌中,58例(1.5%)死于该病。
- 死亡病例组由33例(57%)低分化癌、14例(24%)高细胞变异型乳头状甲状腺癌、4例(7%)Hürthle细胞癌、3例(5%)乳头状微小癌、2例(3%)经典型乳头状甲状腺癌和2例(3%)滤泡变异型乳头状甲状腺癌组成。
- 27例(47%)初诊时即有远处转移,28例(48%)在随访期间发生远处转移,其余3例(5%)存在局部晚期不可切除的复发。
- 36例(62%)存在甲状腺外侵犯,21例(36%)存在广泛血管侵犯。
- 所有微小癌在初诊时临床可见的颈部淋巴结中均含有低分化癌成分。
关键数值与推荐
- 低分化癌占死亡病例的57%,高细胞变异型乳头状甲状腺癌占24%。
- 包膜型甲状腺癌占死亡病例的17%,且全部有广泛血管侵犯和/或初诊远处转移。
- 所有微小癌在初诊时临床可见的颈部淋巴结中均含有低分化癌成分。
临床怎么用
- 初诊时无远处转移、无低分化癌、无甲状腺外侵犯且无广泛血管侵犯可识别几乎无死亡风险的甲状腺癌。
- 初诊时无远处转移的包膜型分化型甲状腺癌伴局灶包膜侵犯和/或血管侵犯似乎不会导致死亡。
- 大多数患者死于远处转移而非局部区域侵犯,促使需要有效的全身治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The vast majority of thyroid cancers, in particular the non-anaplastic follicular cell-derived thyroid carcinomas (non-ANA FCDC), are considered indolent tumors with very low mortality. Hence, it is crucial to analyze the subgroup of these patients who die of disease (DOD) in order to identify clinicopathologic features predictive of disease-specific mortality. METHODS: All non-ANA FCDC operated at a tertiary cancer center between 1985 and 2010 who were DOD were identified and submitted to a meticulous clinicopathologic analysis. RESULTS: Out of 3750 non-ANA FCDC, 58 (1.5%) DOD cases were identified. The DOD group was composed of 33 (57%) poorly differentiated carcinomas (PDTC), 14 (24%) tall-cell variant papillary thyroid carcinomas (TCVPTC), four (7%) Hürthle cell carcinomas, three (5%) papillary microcarcinomas, two (3%) classical variant PTC, and two (3%) follicular variant PTC. Twenty-seven (47%) patients presented with distant metastases (DM), 28 (48%) developed DM during follow-up, while the remaining three (5%) had locally advanced non-resectable recurrence. Gross extension beyond the thyroid (GET) was present in 36 (62%) and extensive vascular invasion (VI) in 21 (36%) of cases. All microcarcinomas had PDTC in their clinically apparent cervical lymph nodes at presentation. Encapsulated thyroid carcinomas were responsible for 17% of DOD cases, and all had extensive VI and/or DM at presentation. All patients had at least one of these high-risk features at diagnosis: DM at presentation, PDTC, GET, and/or extensive VI. The majority of patients died from DM (n = 51; 88%), three (5%) from locoregional disease, three (5%) from both, and one (2%) from unknown cause. CONCLUSIONS: PDTC and TCVPTC are responsible for the vast majority of deaths in differentiated thyroid carcinomas, while the few fatal classical, follicular variant PTC and microcarcinomas all harbor a PDTC component, DM, or GET. Encapsulated differentiated thyroid carcinoma with focal capsular and/or VI without DM at presentation does not seem to cause death. Lack of DM at presentation, PDTC, GET, and extensive VI identify thyroid carcinomas that are at almost no risk of DOD. The vast majority of patients die of DM rather than locoregional invasion, prompting the need for effective systemic treatment.
引用
- Xu B, Ibrahimpasic T, Wang L, et al. Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell-Derived Thyroid Carcinomas. Thyroid. 2016. PMID: 27480016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。